ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

In Brief: NIDR, NCI award $2.8 Million In Grants For Oral Cancer research Centers

October 4, 1996

Advisors’ Report On Intramural Program To Recommend Restructuring

April 14, 1995

Senate Resolution Urges CMS To Reopen Coverage Policy on ESAs In Oncology.

September 7, 2007

Physicians Group Makes No “Simple Recommendation” on Mammograms for Women Aged 40-49.

April 6, 2007

FDA Grants Orphan Designation To Photofrin for Mesothelioma

December 30, 2011

CMS Advisors Express Low Confidence In Low-Dose CT Screening for Lung Cancer

May 9, 2014